Company news
Medicenna Therapeutics Corp. news in 2017
Medicenna Therapeutics Corp.'s news releases, calls and decks from 2017, newest first.
Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
November 16, 2017
Medicenna Presents Clinical Data From Previous Phase 1 and 2 Clinical Trials of MDNA55
November 14, 2017
Medicenna Reports Second Quarter Fiscal 2018 Financial Results
November 13, 2017
Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology
November 9, 2017
Medicenna Announces Presentation at the 2017 Innovations In Cancer Prevention and Research Conference
October 31, 2017
Medicenna Solidifies Superkine Platform with Additional US Patent Issuance
October 24, 2017
Medicenna Announces Trading on the OTCQX Best Market in the United States
October 18, 2017
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55
October 10, 2017
Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma
September 28, 2017
Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting
September 25, 2017
Medicenna Appoints Dr. William Li to Board of Directors
September 21, 2017
Medicenna to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
September 6, 2017
Medicenna Reports First Quarter Fiscal 2018 Financial Results
August 9, 2017
Medicenna Announces Graduation to the TSX
August 1, 2017
Medicenna Bolsters Management Team
July 17, 2017
Medicenna Announces March 31, 2017 Year End Results
June 16, 2017
Medicenna's Immunotherapy Phase 2b Trial Underway Using Brainlab Drug Delivery Technology
June 8, 2017
Medicenna Therapeutics Corp. Opens the Market
May 25, 2017
Medicenna Therapeutics Opens the Market
May 25, 2017
Medicenna Strengthens Patent Portfolio for its Lead Clinical Candidate, MDNA55
April 27, 2017
Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017
April 20, 2017
Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial
April 13, 2017
Medicenna BioPharma Announces Strategic Collaboration with MD Anderson Cancer Center to Advance Next Generation Empowered Cytokines(TM)
March 16, 2017
Medicenna shares resume trading under the symbol "MDNA"
March 8, 2017